Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Deferred Taxes (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Deferred Taxes for 8 consecutive years, with -$49531.0 as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Deferred Taxes rose 7.21% year-over-year to -$49531.0, compared with a TTM value of $3847.0 through Mar 2017, down 99.98%, and an annual FY2017 reading of -$575000.0, changed N/A over the prior year.
  • Deferred Taxes was -$49531.0 for Q1 2017 at Lisata Therapeutics, down from $147286.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $13.6 million in Q4 2015 and bottomed at -$447568.0 in Q2 2013.
  • Average Deferred Taxes over 5 years is $1.0 million, with a median of -$46954.0 recorded in 2016.
  • The sharpest move saw Deferred Taxes plummeted 263.95% in 2013, then skyrocketed 7915.15% in 2015.
  • Year by year, Deferred Taxes stood at -$287779.0 in 2013, then surged by 185.62% to $246385.0 in 2014, then soared by 5433.39% to $13.6 million in 2015, then plummeted by 98.92% to $147286.0 in 2016, then tumbled by 133.63% to -$49531.0 in 2017.
  • Business Quant data shows Deferred Taxes for LSTA at -$49531.0 in Q1 2017, $147286.0 in Q4 2016, and -$46954.0 in Q3 2016.